CELU
Celularity Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.71
−6.56%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.1x
Market Cap
$49.50M
MomentumView details →
1D Return
−6.56%
YTD Return
+68.47%
RSI (14)
72.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.1x
Market Cap
$49.50M
RSI (14)
72.3
MomentumView details →
1D Return
−6.56%
YTD Return
+68.47%
SummaryUpdated Dec 1, 2025
Celularity Inc. (NASDAQ:CELU) is a clinical-stage biotechnology company founded in 2016 and headquartered in Florham Park, New Jersey. The company went public in August 2019 and specializes in developing innovative cell therapies derived from placental tissue. Celularity operates at the intersection of regenerative medicine and immunotherapy, focusing on creating "off-the-shelf" allogeneic cell treatments that can be used across multiple patients without the need for personalized manufacturing. The company has evolved from its initial focus on placental-derived therapies to encompass a broader portfolio including cell banking services and commercialized wound care products.
Similar companies
Latest newsMore news →
Celularity Inc. and MuseCell Innovations announced a U.S. manufacturing collaboration for the Dezawa MuseCell platform at Celularity's Florham Park, New Jersey facility.8d agoCelularity Inc. received a notification letter from Nasdaq on August 21, 2026, stating that the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to its failure to file its Quarterly Report on Form 10-Q for the period ended June 30, 2026, and its continued delinquency in filing the Form 10-Q for the period ended March 31, 2026.10d ago